HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme

E. Florence; S. De Wit; A. Castagna; E. Ribera; A. Hill; H. Vanaken; Y. Van Delft; S. Marks

doi:10.1258/ijsa.2009.009425

HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme

E. Florence, S. De Wit, A. Castagna, E. Ribera, A. Hill, H. Vanaken, Y. Van Delft, S. Marks

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	224-225
Number of pages	2
Journal	International Journal of STD and AIDS
Volume	21
Issue number	3
DOIs	https://doi.org/10.1258/ijsa.2009.009425
Publication status	Published - Mar 2010

ASJC Scopus subject areas

Dermatology
Public Health, Environmental and Occupational Health
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1258/ijsa.2009.009425

Cite this

HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme. / Florence, E.; De Wit, S.; Castagna, A.; Ribera, E.; Hill, A.; Vanaken, H.; Van Delft, Y.; Marks, S.

In: International Journal of STD and AIDS, Vol. 21, No. 3, 03.2010, p. 224-225.

Research output: Contribution to journal › Article › peer-review

@article{4b9221b7975c4d2fa405e33406d76381,

title = "HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme",

author = "E. Florence and {De Wit}, S. and A. Castagna and E. Ribera and A. Hill and H. Vanaken and {Van Delft}, Y. and S. Marks",

year = "2010",

month = mar,

doi = "10.1258/ijsa.2009.009425",

language = "English",

volume = "21",

pages = "224--225",

journal = "International Journal of STD and AIDS",

issn = "0956-4624",

publisher = "SAGE Publications Ltd",

number = "3",

}

TY - JOUR

T1 - HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme

AU - Florence, E.

AU - De Wit, S.

AU - Castagna, A.

AU - Ribera, E.

AU - Hill, A.

AU - Vanaken, H.

AU - Van Delft, Y.

AU - Marks, S.

PY - 2010/3

Y1 - 2010/3

UR - http://www.scopus.com/inward/record.url?scp=77949352785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949352785&partnerID=8YFLogxK

U2 - 10.1258/ijsa.2009.009425

DO - 10.1258/ijsa.2009.009425

M3 - Article

C2 - 20071441

AN - SCOPUS:77949352785

VL - 21

SP - 224

EP - 225

JO - International Journal of STD and AIDS

JF - International Journal of STD and AIDS

SN - 0956-4624

IS - 3

ER -